Scientists in Cambridge developed a new prostate cancer test designed to revolutionize screening, diagnosis, and personalized treatment. The test analyzes blood and urine samples for over 100 clinically-validated prostate-related biomarkers, using an AI-driven algorithm to identify cancer presence, stage, aggressiveness, and genetic risks. This “super test” aims to address the high incidence of prostate cancer (55,000 new cases annually in the UK, over 330,000 in the EU) and improve upon the limitations of current testing methods.
This development is crucial because current prostate cancer testing, like PSA tests and biopsies, can have accuracy rates below 50%. The new test boasts a projected accuracy between 96-99% across diverse age ranges and ethnicities, significantly improving early detection, particularly for high-risk non-caucasian groups. More accurate diagnoses could also reduce the need for unnecessary MRI scans and invasive digital rectal examinations, improving patient experience and healthcare resource allocation.
The test uses a “multi-omics” approach, combining multiple biomarker signatures (proteomic, transcriptomic, genetic/hereditary, and epigenetic) with phenotypic and symptom data analyzed by a proprietary AI algorithm. Each biomarker has been clinically validated in previous trials involving over 31,000 positive prostate cancer samples and 100,000 control samples. EDX Medical Group, the developer, has filed a patent application for the test and algorithm.
This new test could transform prostate cancer management. Its potential for highly accurate early detection and detailed characterization of the disease could lead to more effective and personalized treatment strategies, ultimately improving patient outcomes and survival rates. Further clinical validation and regulatory approvals are being pursued with a target launch date of late 2025 or early 2026.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
